clinical trial · NCT06663722
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
University of Miami·phase2·recruiting·n = 49
Chronic Graft Versus Host DiseasecGVHDAxatilimabExtracorporeal Photopheresis
brief summary
The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).
started
May 5, 2025
primary completion
May 5, 2030
completion
May 5, 2030
last updated
May 15, 2026
official title
A Phase II b Study of Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol